All In Biotech

Drug Trial Radar · NCT00002802

Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma

PHASE III MULTICENTRE TRIAL OF TREATMENT OF NEUROBLASTOMA IN CHILDREN AND ADOLESCENTS

Last checked: Nov 20, 2026Latest source record: Dec 19, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

500

Planned (sponsor's estimate)

Start

Jul 1990

Primary completion

Not stated

Study completion Sep 2003

Sponsor

Lead sponsor
Children's Hospital Medical Center, CincinnatiAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 12, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Primary purpose
Treatment
Who can join
All sexes, up to 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which treatment regimen is most effective in treating patients with different stages of and risk factors for neuroblastoma. PURPOSE: Phase III trial to study the effectiveness of therapy based on stage of disease and risk assessment in treating children with neuroblastoma.

Conditions

  • Neuroblastoma

Interventions

  • carboplatinDrug

  • cisplatinDrug

  • cyclophosphamideDrug

  • dacarbazineDrug

  • doxorubicin hydrochlorideDrug

  • etoposideDrug

  • ifosfamideDrug

  • melphalanDrug

  • mesnaDrug

  • vincristine sulfateDrug

  • vindesineDrug

  • autologous bone marrow transplantationProcedure

  • conventional surgeryProcedure

  • low-LET cobalt-60 gamma ray therapyRadiation

  • low-LET electron therapyRadiation

  • low-LET photon therapyRadiation

  • radioisotope therapyRadiation

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Cologne

    Frechen, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.